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Abstract
Background: Continuous complete clinical remission in T-cell acute lymphoblastic leukemia (T-ALL) is now 
approaching 80% due to the implementation of aggressive chemotherapy protocols but patients that relapse 
continue to have a poor prognosis. Such patients could benefit from augmented therapy if their clinical outcome 
could be more accurately predicted at the time of diagnosis. Gene expression profiling offers the potential to identify 
additional prognostic markers but has had limited success in generating robust signatures that predict outcome across 
multiple patient cohorts. This study aimed to identify robust gene classifiers that could be used for the accurate 
prediction of relapse in independent cohorts and across different experimental platforms.
Results: Using HG-U133Plus2 microarrays we modeled a five-gene classifier (5-GC) that accurately predicted clinical 
outcome in a cohort of 50 T-ALL patients. The 5-GC was further tested against three independent cohorts of T-ALL 
patients, using either qRT-PCR or microarray gene expression, and could predict patients with significantly adverse 
clinical outcome in each. The 5-GC featured the interleukin-7 receptor (IL-7R), low-expression of which was 
independently predictive of relapse in T-ALL patients. In T-ALL cell lines, low IL-7R expression was correlated with 
diminished growth response to IL-7 and enhanced glucocorticoid resistance. Analysis of biological pathways identified 
the NF-κB and Wnt pathways, and the cell adhesion receptor family (particularly integrins) as being predictive of 
relapse. Outcome modeling using genes from these pathways identified patients with significantly worse relapse-free 
survival in each T-ALL cohort.
Conclusions: We have used two different approaches to identify, for the first time, robust gene signatures that can 
successfully discriminate relapse and CCR patients at the time of diagnosis across multiple patient cohorts and 
platforms. Such genes and pathways represent markers for improved patient risk stratification and potential targets for 
novel T-ALL therapies.
Background
T-cell acute lymphoblastic leukemia (T-ALL) affects
approximately 15% of newly diagnosed pediatric ALL
patients. Continuous complete clinical remission (CCR)
in T-ALL patients is now approaching 80% due to the
implementation of aggressive chemotherapy protocols [1-
6]. However, patients that relapse (R) have poor prognosis
and aggressive therapy can lead to long-term side effects
in those that achieve CCR [7]. In the clinical setting, age
and white blood cell count (WBC) at diagnosis are used
to stratify B-lineage ALL patients as either standard or
high risk, significantly impacting on the type and inten-
sity of post-induction therapy used. However these NCI-
defined criteria have been shown to have little prognostic
value in T-ALL disease [1-3]. Improved markers are
needed for outcome prediction to improve T-ALL patient
stratification.
Common karyotypic abnormalities have been identi-
fied in some forms of leukemia and have proven useful
for outcome prediction [8-12]. In precursor B-lineage
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ALL (pre-B ALL), the presence of hyperdiploidy or trans-
locations such as E2A-PBX1, BCR-ABL, or ETV6-RUNX1
contribute to the severity of disease and response to che-
motherapy [8,9]. In T-ALL, increased expression of
TLX1/HOX11  has been associated with favorable out-
come [10,11,13,14], whilst aberrant expression of TAL1,
LYL1  and  TLX3 and deletions at 6q15-16.1 have been
linked to poor prognosis [11,15,16]. Recent work by
Coustan-Smith and colleagues [17] has led to the identifi-
cation of a new very high risk subset of T-ALL (early T-
cell precursor leukemia) that has a distinct expression
profile and immunophenotype. However, due to the lack
of consensus between studies and the small proportion of
T-ALL patients that carry these genetic or molecular
aberrations, the identification of a universal molecular
signature has become a priority. Several studies have
attempted to identify gene signatures that predict induc-
tion failure and/or relapse in T-ALL [8,18,19], but have
had limited success verifying their findings in other
patient cohorts. The current study aimed to identify
robust gene signatures that could be used for the accurate
prediction of relapse at the time of diagnosis, in indepen-
dent patient cohorts, and across different experimental
platforms.
Materials and methods
Patients
The study cohort comprised 84 T-ALL patients treated
on Children's Oncology Group (CCG/COG) protocols
(1882 - 1961) for high risk ALL [4]. Bone marrow speci-
m e n s  w e r e  o b t a i n e d  a t  d i a g n o s i s  f r o m  p a t i e n t s  a t  t h e
Princess Margaret Hospital, Perth, Australia (n = 8) or
COG (n = 76). Ethical approval was obtained from the
Institutional Review Boards, and informed consent for
the use of tissues was obtained for all individuals. These
specimens were assigned to either Training (n = 50) or
Validation (n = 34) Cohorts, based on amount of material
available for microarray and/or quantitative RT-PCR
(qRT-PCR) experiments. Clinical features of these
cohorts are shown in Table 1. All patients achieved remis-
sion following induction therapy; those patients achiev-
ing complete continuous remission (CCR) had median
follow-up times of 7.3 years (Training Cohort) and 8.8
years from diagnosis (Validation Cohort). 44% of the
patients in the Training Cohort and 27% in the Validation
Cohort subsequently relapsed (R).
Gene expression profiling
RNA from the T-ALL Training Cohort (n = 50) was
extracted from bone marrow specimens and hybridized
to HG-U133Plus 2.0 GeneChips (54,675 probe sets;
Affymetrix, Santa Clara, CA, USA) according to Affyme-
trix protocols. Gene expression data were extracted and
normalized using robust multi-array analysis (RMA) [20]
as previously described [21-23]. Expression data from the
two Winter et al cohorts (microarray CEL files and
patient details) were obtained from the authors [19] and
normalized by RMA. Induction failure cases were
removed prior to analysis, resulting in cohort sizes of 44
patients for Pediatric Oncology Group (POG/COG) Pro-
tocol 9404 (30 CCR, 14R, measured on HG-U133 Plus 2.0
arrays) and 41 patients for POG 8704 (24CCR, 17R, mea-
sured on HG-U133A arrays). The modeling approaches
used to develop gene-classifiers (GCs) from microarray
data is described in the results section. For outcome pre-
diction using the obtained GCs, logistic regression was
used to model probability of relapse for each specimen
based on gene expression scores (microarray data or qRT-
PCR data as relevant). This probability was used as a con-
tinuous variable in Cox proportional hazard regression
analysis, and converted into a prediction of CCR/relapse
labels using a probability cut-off point of 50%, generating
model accuracies, sensitivity, specificity, positive predic-
tive values (PPV, the proportion of patients among those
predicted to relapse that actually relapsed) and negative
predictive values (NPV, the proportion of patients among
those predicted as non-relapse that actually achieved
CCR). This stratification was also used for Kaplan-Meier
survival analysis, with significance determined by log-
rank test.
Real-time quantitative RT-PCR (qRT-PCR)
qRT-PCR was performed using TaqMan Gene Expression
Assays (Applied Biosystems, Foster City, CA, USA) as
previously described [21]. Reactions were performed in
duplicate and run on an ABI Prism 7000 sequence detec-
tor (Applied Biosystems). The ACTB gene was used for
normalization and standard curves were utilized for the
quantitation of target gene expression.
Effect of IL7 on cell growth and drug sensitivity
The features of the T-ALL cell lines and culture condi-
tions used in this study have previously been described
[24,25]. RNA for qRT-PCR was extracted from cell lines
in log-phase growth. Surface expression of IL-7Rα
(CD127) was assessed using PE-conjugated anti-human
monoclonal IL-7Rα antibody (Immunotech, Marseilles,
France) and an LSR II flow cytometer (BD Biosciences).
The 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazo-
lium-bromide (MTT) assay was used to determine
growth responses to human recombinant IL-7 (R&D Sys-
tems, Minneapolis, MN) according to our published
methods [24].
Results
Modeling a multi-gene classifier for outcome prediction
Using the decision-tree based algorithm Random Forest
(RF) as previously described [23,26], we ranked theCleaver et al. Molecular Cancer 2010, 9:105
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54,675 probe sets on the HG-U133 Plus 2.0 GeneChip for
their ability to distinguish the 22 R and 28 CCR patients
from the Training Cohort. Starting with the top-ranked
500 probes from this RF analysis we firstly filtered out
probe sets derived from the HG-U133B predecessor
GeneChip (which largely target expressed sequence tags
and non-confirmed gene content), then applied a previ-
ously developed algorithm to identify genes with a high
probability of detection by qRT-PCR [21]. This shortlist
of 57 probe sets (Table S1, Additional file 1) was then
used to model the optimal combination of 5 genes (5 gene
classifier, 5-GC) for outcome prediction in the Training
Cohort. We sought a small classifier of this size to facili-
tate its translation into clinical laboratories for routine
testing at diagnosis. Principle Component Analysis
(PCA) was used to rank gene combinations, based on the
ability of the 1st principal component to explain the vari-
ability between R and CCR patient specimens (r2).
BLAST searches were performed to confirm that probe
sequences were specific for the annotated gene specified,
and TaqMan probes for corresponding sequences were
identified. Logistic regression was used to assess the
accuracy of R/CCR status prediction for each 5-GC. In
this way we identified a 5-GC that could predict R/CCR
outcome in patients from the Training Cohort (n = 50)
with an overall accuracy of 82% (model performance, p <
0.0001; Fisher's Exact Test). These genes were ABTB2,
IL7R, LGALS8, PLAC8, and FAM13A1 (Table 2). Kaplan-
Table 1: Clinical features of T-ALL patients in the Training and Validation Cohorts
Training cohort (n = 50) Validation cohort (n = 34)
CCR (n = 28) Relapse (n = 22) CCR (n = 25) Relapse (n = 9)
Sex
Male/Female 21/7 21/1 14/11 9/0
Age at diag (years)
Median (Range) 13.1 (2.1-16.9) 12.1 (1.8-17.8) 7.1 (2.2-18.3)* 8.8 (1.8-17.5)
WBC (×109/L)
Median (Range) 171.9 (1.1-791) 219.2 (4.9-700) 113.1 (8.2-524.4) 161.8 (13.4-882)
BM blast at diag (%)
Median (Range) 94 (70-100) 91 (74-99) 90 (35-99) 95 (70-99)
Cytogenetics
Normal (46 C) 2 3 13 4
Pseudodiploid (46 C) 12 6 5 2
Hyperdiploid (>47 C) 3 2 3 0
Hypodiploid (<46 C) 0 0 2 1
N/A 11 11 2 2
NCI Risk
Standard 0 0 6 1
High 28 22 19 8
Induction result
M1 25 19 24 8
M2 3 0 0 0
M3 0 0 0 0
N/A 0 3 1 1
Follow-up time (years)
Median (Range) 7.3 (3.3-9.2) 8.8 (4.3-11.9)
Time to relapse (years)
Median (Range) 1.3 (0.2-3.8) 1.4 (0.5-3.3)
WBC, white blood cell count; BM, bone marrow; diag, diagnosis; C, chromosomes; N/A, not available; NCI, National Cancer Institute; M1, 
<5%blasts in BM; M2, 5-25% blasts in BM; M3, >25% blasts in BM. *P = 0.0082 by Mann-Whitney t-test compared to CCR in the training cohort.Cleaver et al. Molecular Cancer 2010, 9:105
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Meier analysis demonstrated that patients labeled as R
and CCR using gene expression scores of the 5-GC had
significantly different relapse-free survival times (Figure
1A, p < 0.0001). Cox proportional regression analysis of
age, WBC, gender and 5-GC score demonstrated that the
5-GC score was the most significant factor related to out-
come (p < 0.0001, Table 3). The fact that age, WBC and
gender were not significantly associated with outcome in
the present study is a reflection of the size of the cohort
involved and emphasizes the need for additional prog-
nostic markers. Expression of the 5-GC was also mea-
sured by qRT-PCR in 40 specimens from the Training
Cohort for which sufficient material was available. Table
2 summarizes the expression levels and R/CCR fold-
changes for the identified genes, measured by both
microarray and qRT-PCR. The recorded fold-changes
were comparable between microarray and qRT-PCR data
and the data correlated significantly between the two
techniques (p < 0.001) for all genes (Pearson's correlation,
log2 values).
Validation of the 5-GC in an independent cohort
We subsequently determined the expression levels of the
genes in the 5-GC by qRT-PCR in diagnostic bone mar-
row specimens from 34 pediatric T-ALL patients from a
completely independent Validation Cohort. Most of these
patients were treated on COG 1882 or 1901, while the
p a t i e n ts  i n  t h e  T r a i n i n g  C o h o rt  w e r e  t r e a t ed  o n  C OG
1961 [4]. In the Validation Cohort the 5-GC yielded an
overall prediction accuracy of 79% (Table 4). Whilst
model-performance was borderline by Fisher's Exact Test
(p = 0.064, Table 4), Kaplan-Meier analysis demonstrated
significant differences in relapse-free survival (Figure 1B,
p < 0.0001). Although there was low sensitivity with only
2/9 relapsing patients successfully identified, PPV and
specificity were 100%, meaning that no patients were
incorrectly identified as relapsers. Cox proportional
regression analysis confirmed the 5-GC score to be a sig-
nificant factor related to outcome in this cohort (p < 0.05,
Table S2, Additional file 1).
In silico verification across multiple platforms and studies
A number of other studies have attempted to find out-
come predictors in pediatric T-ALL using gene expres-
sion at the time of diagnosis. Yeoh, et al[8] identified
seven genes (UQCRFS1,  SMA5,  PRPSAP2,  NCAPD3,
TXBAS1,  HMRPH2  and  CD44) as being differentially
expressed between R and CCR in a cohort of 37 T-ALL
patients using U95Av2 arrays. Our own group has previ-
ously identified three genes, CFLAR,  NOTCH2  and
BTG3, as prognostic markers in a smaller study of 12 T-
ALL patients using HG-U133A arrays [18]. None of these
previously identified prognostic markers featured in the
top list of informative genes from the present study. In a
different approach, Ferrando and colleagues [11] have
demonstrated the predictive value of molecular signa-
tures linked to oncogene expression (TLX1, TAL1, LYL1,
LMO1, and LMO2) in T-ALL. However, the expression of
these individual oncogenes did not significantly predict
outcome in the present study. These observations dem-
onstrate the difficulty of developing gene-based classifi-
ers that can predict outcome across multiple platforms
and patient cohorts.
In a recently published article, Winter et al[19] used
HG-U133-Plus 2.0 GeneChips in pediatric T-ALL
patients with the aim of identifying a gene signature in
diagnosis specimens that could be linked to relapse or
induction failure. The study comprised a cohort of 50
Table 2: Expression of genes from the 5-GC measured by both array (HG-U133Plus2) and qRT-PCR in specimens from the 
Training Cohort
Gene Symbol 
(Probe ID)
Gene RF 
Rank
Mean Expression (Array) Fold Change (R/CCR) r
RC C R A r r a y q R T - P C R
ABTB2 
(213497_at)
Ankyrin repeat and BTB 
(POZ) domain-containing 2
12 119.8 89.7 1.34 3.11 0.76
IL7R 
(205798_at)
Interleukin-7 receptor 43 292.0 542.7 0.54 0.47 0.92
LGALS8 
(208936_x_at)
Lectin, galactose binding, 
(Galectin 8)
288 197.4 231.8 0.85 0.37 0.56
PLAC8 
(219014_at)
Placenta-specific 8 (Onzin) 297 530.4 979.5 0.54 0.22 0.90
FAM13A1 
(217047_s_at)
Family with sequence 
similarity 13, member A1
356 70.0 84.0 0.83 0.30 0.69
r, correlation between HG-U133Plus2 and qRT-PCR fold change data (n = 40); R, relapse; CCR, continuous complete remission.Cleaver et al. Molecular Cancer 2010, 9:105
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patients treated on therapy protocol COG 9404 and a
cohort of 42 patients treated on POG 8704, but was
unable to identify a gene signature to distinguish R from
CCR cases. However, a gene signature linked to induction
failure was identified. Comparison of this induction fail-
ure signature with our 500 top-ranked genes in the pres-
ent study indicated just one gene in common, hexokinase
II, which ranked #101 in the Winter et al gene list and #65
in our list and was upregulated in patients that went on to
relapse. This gene is of interest because of its role in coor-
dinating metabolic and apoptotic pathways at the mito-
chondrial membrane, and its reported association with
glucocorticoid resistance in T-ALL [25]. To verify our
own gene classifier in the two cohorts studied by Winter
et al, we downloaded the array data from their study,
removed the induction failure cases, and applied the 5-
GC in logistic regression to predict R/CCR status in the
remaining patients. The 5-GC predicted patient outcome
with an overall accuracy of 75% in the COG 9404 cohort,
and 68% in the POG 8704 cohort (Table 4). Importantly,
patients predicted to relapse by the 5-GC had signifi-
cantly worse survival rates in both cohorts (p < 0.05 for
both, Figure 1C &1D). The weighted averages for the
model performance across the four cohorts are summa-
rized in Table 4 along with a combined p-value (gener-
ated by global assessment of performance accuracies in
each independent cohort). Whilst the p-values for model
performance were borderline in the three test-back
cohorts individually, the consistent performance over all
four cohorts was highly significant (p < 0.0001, Table 4).
This combined analysis remained highly significant when
the results from the original Training Cohort were
excluded (p < 0.0005). Taken together these data indicate
that the 5-GC has prognostic relevance across four inde-
pendent T-ALL patient cohorts.
Functional relevance of the IL-7R as a prognostic marker
Of the genes identified as part of the 5-GC, the IL-7R is of
particular relevance to T-ALL since IL-7 is known to be a
key regulator of T-cell development [27]. Kaplan-Meier
analysis in the Training Cohort demonstrated that low
expression of the IL-7R, as a single variable, was signifi-
cantly predictive of adverse outcome (p < 0.001, Figure
2A). To assess the functional significance of variations in
IL-7R expression, we studied seven T-ALL cell lines [24],
assessing IL-7R mRNA expression by qRT-PCR (Figure
2B) and cell surface expression by flow cytometry (Figure
2C). A significant correlation was demonstrated between
mRNA and protein expression in the cell lines (p < 0.05),
with some lines demonstrating little or no IL-7R expres-
sion (HSB2, JURKAT, PER-255). To examine the relation-
ship between IL-7R expression and drug sensitivity we
examined microarray gene signatures that we have previ-
ously correlated with glucocorticoid resistance patterns
in an extended panel of 15 T-ALL cell lines [25], that
includes those shown in Figure 2. Across the 15 lines
there was a significant inverse correlation between
mRNA expression of the IL-7R and IC50 scores to both
dexamethasone (r = -0.673; p < 0.01) and methylpredni-
solone (r = -0.631, p < 0.02, Pearson's correlations), such
that low IL-7R mRNA expression corresponded to gluco-
corticoid resistance. Thus the mean IC50 for the low IL-
7R expressing lines in Figure 2C (HSB2, JURKAT, and
PER-255) is three orders of magnitude higher (167 μg/ml
DEX; 259 μg/ml MPRED) than for the four high express-
ing lines (0.03 μg/ml DEX; 0.06 μg/ml MPRED). Figure
2D demonstrates that only lines expressing IL-7R at rela-
Table 3: Univariate Cox proportional hazard regression analyses of the risk of relapse in the Training Cohort (n = 50) in 
relation to diagnostic features and the 5-GC score
Variable No. of
Patients
Hazard Ratio 95% CI a p-value
Age at diagnosis
<10 years 17 1 b)
≥10 years 33 1.3 (0.506, 3.32) 0.59
WBC
<50/nl 12 1 b)
>50/nl 38 1.15 (0.425, 3.12) 0.78
Gender
Female 8 1 b)
Male 42 5.53 (0.742, 41.2) 0.095
5-GC score 50 1.31 (1.19, 1.44) <0.0001
a) 95% confidence interval; b) reference group.Cleaver et al. Molecular Cancer 2010, 9:105
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tively high levels respond to the addition of exogenous
recombinant IL-7. Together these data are consistent
with previous observations, made using primary T-ALL
specimens, that IL-7 non-responsiveness correlates with
reduced response to glucocorticoid therapy, and is thus
an adverse prognostic indicator [28].
Outcome prediction modeling using enriched biological 
pathways
The 5-GC model was developed through a process of sta-
tistical, rather than biological, modeling to generate a
robust diagnostic classifier. Although the individual genes
that comprise the 5-GC have links to cancer biology and
tumor development (see Discussion) we do not propose
that they represent a coherent biological signature to
explain clinical relapse. As a complementary approach
therefore, we turned to Gene Set Enrichment Analysis
(GSEA, http://www.broad.mit.edu/gsea) [29] to gain
insight into the biological pathways differentially regu-
lated in R vs. CCR specimens. Analysis was performed
using the ranked gene list from the RF performed in the
Training Cohort (focusing on HG-U133A probesets
only), and three biological gene sets were identified at the
relevant false discovery rate (FDR) < 25% and nominal p-
value < 0.001. These were (i) NFκB pathway regulated
genes, (ii) Genes of the Wnt/Ca2+/cGMP pathway (Global
Cancer Map, Broad Institute), and (iii) Genes with cell
a d h e s i o n  r e c e p t o r  a c t i v i t y  ( G l o b a l  C a n c e r  M a p ,  B r o a d
Institute). The genes from these pathways that contribute
most to the observed phenotype are referred to as the
'leading edge' and are listed in Table S3, Additional file 1.
These leading edge genes were used in logistic regression
to model outcome based on expression of each of the
three pathways. Outcome prediction using the NFkB-
Figure 1 Kaplan-Meier survival curves for patients predicted as CCR or relapse using the 5-GC model in (A) Training Cohort (n = 50); (B) Val-
idation Cohort (n = 34); (C) COG 9404 (Winter et al, n = 44); (D) POG 8704 (Winter et al, n = 41).
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Table 4: Validation of gene-classifier models for outcome prediction across multiple T-ALL cohorts
Model Cohort Acc PPV NPV Sens Spec P-value
5-GC
(5 genes)
Training 82 81 83 77 86 9.4 × 10-6
Validation 79 100 78 22 100 0.064
COG 9404† 75 71 76 36 93 0.025
POG 8704† 68 83 66 29 96 0.066
Combined 76 81 75 47 93 1.5 × 10-9 (1.2 
× 10-4)
Pathway NFκB
(7 genes)
Training 76 71 81 77 75 4.8 × 10-4
V a l i d a t i o n ----- -
COG 9404† 77 83 76 36 97 0.009
P O G  8 7 0 4 † 5 64 45 92 47 9 1
Combined 70 67 72 49 84 7.2 × 10-5 (0.073)
Pathway
Wnt/Ca2+/cGMP
(12 genes)
Training 76 75 77 68 82 4.6 × 10-4
V a l i d a t i o n ----- -
COG 9404† 75 67 77 43 90 0.019
P O G  8 7 0 4 † 6 86 37 25 97 5 0 . 0 5
Combined 73 69 76 58 83 8.7 × 10-7 
(0.0011)
Pathway
Cell Adhesion
(14 genes)
Training 82 84 81 73 89 8.6 × 10-6
V a l i d a t i o n ----- -
COG 9404† 75 62 81 57 83 0.012
P O G  8 7 0 4 † 8 58 78 57 69 2 1 . 1  ×  1 0 -5
Combined 81 79 82 70 88 8.2 × 10-12 
(4.5 × 10-7)
Cohorts represent the Training Cohort (HG-U133Plus2, n = 50), Validation Cohort (qRT-PCR, n = 34), COG 9404 (HG-U133Plus2, n = 44), and 
POG 8704 (HG-U133A, n = 41); Acc, Accuracy; PPV, Positive Predicted Value; NPV, Negative Predicted Value; Sens, Sensitivity; Spec, Specificity 
(all model performances given as % and combined using means weighted for cohort size and CCR/relapse patient composition); P-value, 
Fisher's Exact Test of individual or combined model performances across the four cohorts (significance with the omission of the Training 
Cohort given in parenthesis); † Microarray cohorts downloaded from Winter et al (2007).
pathway or Wnt/Ca2+/cGMP pathway models returned
accuracies of >75% in both the Training Cohort, and the
COG 9404 cohort, but did not perform so strongly in the
POG 8704 cohort (Table 4). However, the cell adhesion
receptor pathway model accurately predicted outcome
(75-85%) in all three cohorts (Table 4). These perfor-
mances were significant in each of the individual cohorts
and highly significant in the global analysis (p < 0.0001,
Table 4). Kaplan-Meier plots demonstrated that patients
predicted to relapse using this model had significantly
reduced relapse-free survival times in all three cohorts
(Figure 3).
Discussion
The fate of children who relapse with T-ALL remains dis-
mal. This has fuelled considerable research into the dis-
covery of ' risk factors ' tha t are indicative of a pa tient's
likelihood of relapse before post-induction therapy is pre-Cleaver et al. Molecular Cancer 2010, 9:105
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scribed. Our study statistically modeled a 5-GC that suc-
cessfully predicted T-ALL patient outcome in four
independent studies across different platforms. In a com-
plementary approach we used biological signatures to
successfully model patient outcome in these studies. To
our knowledge this is the first time gene classifiers have
been developed that accurately model ALL relapse in
more than two independent cohorts. It is important to
note that the models described here could not be used to
down-grade a patient's risk classification since predic-
tions of outcome under these models is in the context of
the therapy each patient actually received. Thus CCR
patients in these cohorts may potentially have relapsed if
treated with lesser therapy. However, it would be possible
to use such models to augment therapy. In the case of
patients already stratified as high-risk (the majority of T-
ALLs), this could include bone marrow transplant in first
remission [6] or the use of experimental therapeutics.
The best models generated in this study (the 5-GC and
Cell Adhesion Pathway) were associated with good aver-
age specificity across the four cohorts (88-93%), but
achieved lower average sensitivity (47-70%). In clinical
Figure 2 Functional relevance of IL-7R as a prognostic marker. (A) Kaplan-Meier survival curves based on levels of IL-7R (qRT-PCR mRNA expres-
sion tertiles) in the Training Cohort; (B) IL-7R mRNA expression in a panel of T-ALL cell lines measured by qRT-PCR; (C) Cell surface IL-7R (CD127) protein 
expression in T-ALL cell lines measured by flow cytometry; (D) Growth response of T-ALL cell lines over 4 days to exogenous IL-7 (10 ng/ml) as mea-
sured by MTT (% proliferation compared to medium control).
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terms this means that application of these models as a
diagnostic test could have successfully identified up to
two-thirds of the patients in these cohorts destined to
relapse, whilst potentially over-treating only a small per-
centage of patients (7-12%) that would have achieved
CCR under current protocols. Although higher sensitiv-
ity would be desirable, the correct identification of even a
few patients destined to relapse could further improve
cure rates.
In recent years much criticism has been directed
towards microarray studies aiming to identify gene mark-
ers from small cohorts. Owing to the dimensionality of
the data it is often possible to select genes at random that
can discriminate between two phenotypes or patient sub-
groups with surprising accuracy. Furthermore, many sta-
tistical tools over-fit data such that the ability of
classifiers to discriminate between phenotypes only
extends to the cohort in which they were developed.
However the probability of selecting gene classifiers at
random that can discriminate between phenotypes in
more than one cohort is vanishingly small. Validation of
classifiers across multiple cohorts as described here
(especially those identified using a permutative resam-
pling algorithm such as the Random Forest) is empirical
evidence of their robustness.
In this study low expression of the IL-7R was recorded
in diagnostic T-ALL specimens from patients who later
relapsed, linking low IL-7R expression to eventual therapy
failure. The IL-7 cytokine is normally essential for T-cell
development, survival and proliferation [27], and can
inhibit both spontaneous apoptosis [28] and the apop-
totic responses to chemotherapeutic agents in T-ALL
[30], with the level of expression of the IL-7R correlating
with these responses [28]. As such, IL-7 has been pro-
posed as an important factor supporting leukemogenesis
[31], but a proportion of T-ALL patients have blasts that
do not respond to IL-7 [28]. This latter observation has
been correlated with tumor maturation stage but it is also
possible that it represents the acquisition of growth-fac-
tor independence. Growth-factor independence is a clas-
sical hallmark of a successful cancer cell [32] and
indicates the development of potent pro-survival mecha-
nisms. Importantly, T-ALL patients with an IL-7 non-
responsive phenotype demonstrate poorer clinical
responses to glucocorticoid therapy and thus have an
adverse prognosis [28], consistent with our own findings
in the present study.
Despite the obvious relevance of the IL-7R for T-ALL,
the genes of the 5-GC were not selected on the basis of
biological function. As such the 5-GC is considered as a
tool for prognosis rather than for the interpretation of
mechanisms of relapse, although the individual genes
themselves do have links with cancer. The ABTB2 gene is
involved with protein-protein interactions through its
ankyrin repeats and BTB (POZ) domains. Although its
specific function is unknown, one study has reported the
up-regulation of ABTB2  in gastric tumor metastasis,
highlighting the possible role of this gene in aggressive
malignant phenotypes [33]. The FAM13A1 gene has an
unknown function but is induced in various cell types
exposed to hypoxic conditions [34]. It has been reported
to be down-regulated in malignant thyroid tissue [35] but
up-regulated in ovarian and breast cancer with links to
poor prognosis [34]. PLAC8  is conserved in all verte-
brates and is expressed at high levels in immune cell types
[36]. The function of this gene is also unclear but has
Figure 3 Kaplan-Meier survival curves for patients predicted as 
CCR or relapse using the 14 gene 'Cell Adhesion Receptor' biolog-
ical model in (A) Training Cohort (n = 50); (B) COG 9404 (Winter et 
al, n = 44); (C) POG 8704 (Winter et al, n = 41).
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been linked to proliferation and apoptosis. PLAC8  is
over-expressed in hepatocellular carcinoma tumours [37]
and reduced in Paclitaxel-resistant prostate cancer [38].
Our alternative approach focused on identifying bio-
logical pathways that are involved in the progression to
therapy failure in T-ALL. The NFκB and Wnt signaling
pathways both had significant predictive power in this
regard. The NF-κB pathway is highly active in T-ALL and
is one of the major mediators of NOTCH1-induced trans-
formation, establishing NFκB as a potentially promising
target for T-ALL therapy [39]. The Wnt pathway is also
important for T cell development and proliferation and is
deregulated in several types of leukemia [40]. Although
few studies have directly reported a role for Wnt signaling
in the pathogenesis of T-ALL, antagonism of Wnt signal-
ing has been shown to lead to chemotherapy resistance in
a model of acute myeloid leukemia, via the downstream
action of NFκB [41]. The pathway model that predicted
relapse with the highest accuracy across all four cohorts
in the present study was the Cell Adhesion Receptor
geneset, with 12 out of the 14 genes representing integ-
rins (Table S3, Additional file 1). Interestingly, LGALS8,
the final member of the 5-GC, codes for a secreted mam-
malian beta-galactosidase binding protein (galectin-8)
that binds with high affinity to a variety of cell surface
integrins, thereby modulating cell adhesion and cell sur-
vival [42,43]. Adhesion between host and tumor cells, and
extrinsic signals within the tumor microenvironment can
promote an optimal niche for tumor cell survival and is
an essential component of tumor invasion and metastasis
[44,45]. New strategies for therapy have consequently
been designed to disrupt these tumor-stromal cell inter-
a c t i o n s .  F o r  e x a m p l e ,  t h e  i n h i b i t i o n  o f  C X C R 4  ( a  k e y
receptor for tumor cell migration and adhesion) has been
shown to overcome stromal-cell mediated drug resis-
tance in acute myeloid leukemia and chronic lymphocytic
leukaemia [46]. Clinical trials using specific integrin
inhibitors have also shown promise in different types of
solid tumours [47,48]. Clearly cell adhesion interactions
have an important role to play in tumor progression; the
observations from the present study indicate that they
may also contribute to the mechanisms that lead to dis-
ease recurrence in ALL.
Conclusions
We have used two different approaches to identify gene
signatures that can successfully discriminate relapse and
CCR patients at the time of diagnosis across multiple
patient cohorts and platforms. Defined gene classifiers
(such as the 5-GC) containing a smaller number of genes
may be useful to augment existing risk stratification regi-
mens for patients diagnosed with ALL as they can easily
be adapted to qRT-PCR technology [18,22]. The comple-
mentary method we present here uses larger, biologically
defined genesets that provide important clues to the
u n d e r l y i n g  m e c h a n i s m s  o f  r e l a p s e .  S u c h  i n s i g h t s  m a y
provide for the development of improved therapies for T-
ALL.
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